{"id":"W4415751687","doi":"10.1016/j.jchf.2025.102706","title":"Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure","year":2025,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Heart Institute; University of Alberta","funders":"National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; Respicardia; American Regent; Sanofi Pasteur; Abbott Vascular; Intas Pharmaceuticals; Institut de Cardiologie de Montréal; Daiichi Sankyo Europe; Servier; Vifor Pharma; MyoKardia; Novo Nordisk; GlaxoSmithKline; Gedeon Richter; Sanofi; Abiomed; Alexion Pharmaceuticals; University of Glasgow; Horizon Therapeutics; Pfizer; Moderna; Sarepta Therapeutics; British Heart Foundation; Duke Clinical Research Institute; Cytokinetics; National Institutes of Health; Regeneron Pharmaceuticals; Defense Acquisition Program Administration; Boston Scientific Corporation; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Boehringer Ingelheim; Amgen; Alnylam Pharmaceuticals","keywords":"Heart failure; Natriuretic peptide; Urinary system; Phase (matter); Heart disease; Chronic renal failure","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001361965,0.001887932,0.003445637,0.0005575011,0.0005630581,0.0009318348,0.001145441,0.001940077,0.008396744],"category_scores_gemma":[0.001402857,0.0009745511,0.0008799638,0.0004077385,0.001172912,0.001025647,0.0003499961,0.002148356,0.001297507],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006571828,"about_ca_system_score_gemma":0.001636266,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008924408,"about_ca_topic_score_gemma":0.002074823,"domain_scores_codex":[0.9995543,0.000175255,0.00002580658,0.0001006038,0.00004574202,0.00009818732],"domain_scores_gemma":[0.9993666,0.0001395466,0.0001234037,0.00005284473,0.00006593588,0.0002517835],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9707173,0.0125507,0.0004486956,0.0004498005,0.0003479361,0.00003540914,0.00003077303,0.0001894166,0.004937578,0.00008193644,0.0007566051,0.009453763],"study_design_scores_gemma":[0.9613405,0.0368794,0.000893803,0.000009467606,0.0001060277,0.00001515046,0.000008054063,0.000174587,0.000221663,0.00003877023,0.000305342,0.000007346328],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807314,0.003102545,0.001110256,0.0007208994,0.0009113422,0.009087681,0.001672499,0.0002838592,0.00237954],"genre_scores_gemma":[0.9673276,0.003061482,0.003484163,0.002360918,0.001000988,0.01475069,0.001782483,0.00005487979,0.006176739],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008396744,"threshold_uncertainty_score":0.02808988,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01076876286501805,"score_gpt":0.2956765989470982,"score_spread":0.2849078360820802,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}